[
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Unveils $5B Virginia Facility to Ramp Up Bioconjugate and Monoclonal Antibody Production",
    "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Eli Lilly and Company is one of them. Eli Lilly and Company (NYSE:LLY) tops our list for being one of the best pharmaceutical stocks. It is the Indianapolis-based pharmaceutical giant and is accelerating its dominance in […]",
    "url": "https://finnhub.io/api/news?id=ec92f70362726fb6ae89af7c80b176f07cc779711119690f635f1fe16735d4cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758668504,
      "headline": "Eli Lilly and Company (LLY) Unveils $5B Virginia Facility to Ramp Up Bioconjugate and Monoclonal Antibody Production",
      "id": 136858110,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Eli Lilly and Company is one of them. Eli Lilly and Company (NYSE:LLY) tops our list for being one of the best pharmaceutical stocks. It is the Indianapolis-based pharmaceutical giant and is accelerating its dominance in […]",
      "url": "https://finnhub.io/api/news?id=ec92f70362726fb6ae89af7c80b176f07cc779711119690f635f1fe16735d4cf"
    }
  },
  {
    "ts": null,
    "headline": "Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?",
    "summary": "Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).",
    "url": "https://finnhub.io/api/news?id=54f4cd504bf42239ad333789ab57451e151f59893e508226cefb66f6d500d3c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758668100,
      "headline": "Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?",
      "id": 136858111,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).",
      "url": "https://finnhub.io/api/news?id=54f4cd504bf42239ad333789ab57451e151f59893e508226cefb66f6d500d3c2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Falls More Steeply Than Broader Market: What Investors Need to Know",
    "summary": "In the closing of the recent trading day, Eli Lilly (LLY) stood at $746.98, denoting a -1.06% move from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=36004b9cd2950db22cb140dfbf731787e1fff022cdd142576c4d38e0cef32560",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758663903,
      "headline": "Eli Lilly (LLY) Falls More Steeply Than Broader Market: What Investors Need to Know",
      "id": 136858112,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Eli Lilly (LLY) stood at $746.98, denoting a -1.06% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=36004b9cd2950db22cb140dfbf731787e1fff022cdd142576c4d38e0cef32560"
    }
  },
  {
    "ts": null,
    "headline": "Top Analyst Reports for Apple, Eli Lilly & Chevron",
    "summary": "Apple grows Services with over 1B subscribers, while Eli Lilly and Chevron face mixed industry and market dynamics.",
    "url": "https://finnhub.io/api/news?id=fe86442bade40a951990c8fa285c4d2a65f448c2dd0e750497812f32c154d28d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758660300,
      "headline": "Top Analyst Reports for Apple, Eli Lilly & Chevron",
      "id": 136857439,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Apple grows Services with over 1B subscribers, while Eli Lilly and Chevron face mixed industry and market dynamics.",
      "url": "https://finnhub.io/api/news?id=fe86442bade40a951990c8fa285c4d2a65f448c2dd0e750497812f32c154d28d"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Edge Higher Late Afternoon",
    "summary": "Health care stocks edged higher late Tuesday afternoon, with the NYSE Health Care Index adding 0.1%",
    "url": "https://finnhub.io/api/news?id=27a42f39c520d30361c9a0ef7bc0fbda2c8c64f3fb0189309b672c34248b08c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758656965,
      "headline": "Sector Update: Health Care Stocks Edge Higher Late Afternoon",
      "id": 136855489,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks edged higher late Tuesday afternoon, with the NYSE Health Care Index adding 0.1%",
      "url": "https://finnhub.io/api/news?id=27a42f39c520d30361c9a0ef7bc0fbda2c8c64f3fb0189309b672c34248b08c8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Build $6.5 Billion Texas Facility to Boost U.S. Ingredient Manufacturing",
    "summary": "The planned site, which will be used to manufacture the company’s first oral weight-loss drug, is expected to be operational within five years.",
    "url": "https://finnhub.io/api/news?id=4eeeb3bf29c9d86f37aeaba2cb88bd54186383686b4f8a106b9f0a079eb71333",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758650460,
      "headline": "Eli Lilly to Build $6.5 Billion Texas Facility to Boost U.S. Ingredient Manufacturing",
      "id": 136855490,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The planned site, which will be used to manufacture the company’s first oral weight-loss drug, is expected to be operational within five years.",
      "url": "https://finnhub.io/api/news?id=4eeeb3bf29c9d86f37aeaba2cb88bd54186383686b4f8a106b9f0a079eb71333"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to build new USD6.5 billion manufacturing facility in Texas",
    "summary": "Eli Lilly to build new USD6.5 billion manufacturing facility in Texas",
    "url": "https://finnhub.io/api/news?id=0312022b8b5eb63e4f2abc6a6c7c36f1fbecc45f9b77a220868e1e54046889e8",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758648546,
      "headline": "Eli Lilly to build new USD6.5 billion manufacturing facility in Texas",
      "id": 136852241,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=0312022b8b5eb63e4f2abc6a6c7c36f1fbecc45f9b77a220868e1e54046889e8"
    }
  },
  {
    "ts": null,
    "headline": "Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas",
    "summary": "Eli Lilly and Company (NYSE: LLY) announced today that it plans to build a new $6.5 billion manufacturing facility at Generation Park in Houston, Texas. This planned next-generation synthetic medicine active pharmaceutical product (API) facility, the second of four new U.S. sites Lilly will announce this year, will focus on manufacturing the company's pipeline of small molecule medicines across therapeutic areas, including cardiometabolic health, oncology, immunology and neuroscience. It is expe",
    "url": "https://finnhub.io/api/news?id=019f060e356792f3f3301a1e8a4edb865beb364b4d37ffb286b28922174b5add",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758646800,
      "headline": "Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas",
      "id": 136850293,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) announced today that it plans to build a new $6.5 billion manufacturing facility at Generation Park in Houston, Texas. This planned next-generation synthetic medicine active pharmaceutical product (API) facility, the second of four new U.S. sites Lilly will announce this year, will focus on manufacturing the company's pipeline of small molecule medicines across therapeutic areas, including cardiometabolic health, oncology, immunology and neuroscience. It is expe",
      "url": "https://finnhub.io/api/news?id=019f060e356792f3f3301a1e8a4edb865beb364b4d37ffb286b28922174b5add"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=6bd6fbe406c53747e06d66b976cc640c7e8a0b4a018ecfad3db4ff87b6211589",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758645060,
      "headline": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
      "id": 136867272,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=6bd6fbe406c53747e06d66b976cc640c7e8a0b4a018ecfad3db4ff87b6211589"
    }
  },
  {
    "ts": null,
    "headline": "Can PFE Successfully Return to the Obesity Space With Metsera Buyout?",
    "summary": "Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.",
    "url": "https://finnhub.io/api/news?id=9a2ba6748f1ef7cb2b9739e59f5abfc8c9b43a062b5604ecf47fb0f655cc5775",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758644160,
      "headline": "Can PFE Successfully Return to the Obesity Space With Metsera Buyout?",
      "id": 136850972,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.",
      "url": "https://finnhub.io/api/news?id=9a2ba6748f1ef7cb2b9739e59f5abfc8c9b43a062b5604ecf47fb0f655cc5775"
    }
  },
  {
    "ts": null,
    "headline": "LifeSpan Portfolio Company Remedium Signs Landmark Deal with Eli Lilly",
    "summary": "Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio, Inc. (\"Remedium\"), has entered into a multi-target research and development collaboration with Eli Lilly and Company (\"Lilly\") focused on advancing innovative gene therapies for Type 2 diabetes and obesity.",
    "url": "https://finnhub.io/api/news?id=c21a001173776ac424afee38d59a79839afba6de7c185caaac2159e723ea0111",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758638220,
      "headline": "LifeSpan Portfolio Company Remedium Signs Landmark Deal with Eli Lilly",
      "id": 136850294,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio, Inc. (\"Remedium\"), has entered into a multi-target research and development collaboration with Eli Lilly and Company (\"Lilly\") focused on advancing innovative gene therapies for Type 2 diabetes and obesity.",
      "url": "https://finnhub.io/api/news?id=c21a001173776ac424afee38d59a79839afba6de7c185caaac2159e723ea0111"
    }
  },
  {
    "ts": null,
    "headline": "Can oral GLP-1RAs deliver on the promise of accessible obesity care?",
    "summary": "Eli Lilly and Novo Nordisk are in a tight race to capture the lucrative oral obesity drug market – but how will their competing treatments reshape the landscape?",
    "url": "https://finnhub.io/api/news?id=fcc60b347f0722aad141e34ce2db0a6b427c2c429a851ead27a5d95c6e963fd1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758636905,
      "headline": "Can oral GLP-1RAs deliver on the promise of accessible obesity care?",
      "id": 136850295,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Novo Nordisk are in a tight race to capture the lucrative oral obesity drug market – but how will their competing treatments reshape the landscape?",
      "url": "https://finnhub.io/api/news?id=fcc60b347f0722aad141e34ce2db0a6b427c2c429a851ead27a5d95c6e963fd1"
    }
  },
  {
    "ts": null,
    "headline": "UBS slashes global GLP-1 sales estimate for 2030 on softer outlook",
    "summary": "Investing.com -- UBS has cut its global GLP-1 sales forecast for 2030 to $130 billion, down from over $150 billion, citing weaker-than-expected data from next-generation assets and compounded product disruptions in the US market.",
    "url": "https://finnhub.io/api/news?id=a58ff7849e06cc4a7e0d32b5e8eadd19177ffe2446c5654cfd9af002ff7daab0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758635251,
      "headline": "UBS slashes global GLP-1 sales estimate for 2030 on softer outlook",
      "id": 136850296,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- UBS has cut its global GLP-1 sales forecast for 2030 to $130 billion, down from over $150 billion, citing weaker-than-expected data from next-generation assets and compounded product disruptions in the US market.",
      "url": "https://finnhub.io/api/news?id=a58ff7849e06cc4a7e0d32b5e8eadd19177ffe2446c5654cfd9af002ff7daab0"
    }
  },
  {
    "ts": null,
    "headline": "Prellis Biologics Enters Multi-Target Drug Discovery & Development Collaboration with Lilly to Advance Human Antibody Therapeutics",
    "summary": "Prellis Biologics, Inc., a biotechnology company innovating human antibody discovery through organoid & artificial intelligence enabled technology, announced a multi-target drug discovery collaboration with Eli Lilly and Company (\"Lilly\"). In this strategic collaboration, the unique capabilities of Prellis' EXIS™ and AntiGen AI platforms will accelerate the discovery of highly diverse and fully human antibodies for multiple disease targets.",
    "url": "https://finnhub.io/api/news?id=a0c87016ecaa0206036bea5a7688103f8ff7b2eb90d67496c9035d9c3abd9886",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758632400,
      "headline": "Prellis Biologics Enters Multi-Target Drug Discovery & Development Collaboration with Lilly to Advance Human Antibody Therapeutics",
      "id": 136850297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Prellis Biologics, Inc., a biotechnology company innovating human antibody discovery through organoid & artificial intelligence enabled technology, announced a multi-target drug discovery collaboration with Eli Lilly and Company (\"Lilly\"). In this strategic collaboration, the unique capabilities of Prellis' EXIS™ and AntiGen AI platforms will accelerate the discovery of highly diverse and fully human antibodies for multiple disease targets.",
      "url": "https://finnhub.io/api/news?id=a0c87016ecaa0206036bea5a7688103f8ff7b2eb90d67496c9035d9c3abd9886"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health Drives Drug Affordability by Promoting Competition",
    "summary": "CVS strengthens Caremark's PBM edge with formulary shifts, new partnerships and cost-saving wins for clients.",
    "url": "https://finnhub.io/api/news?id=6ab643017ac2470a0b23e3fb3e0524ab2f46f27856d880ccdb1d8d6424ccae53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758630180,
      "headline": "CVS Health Drives Drug Affordability by Promoting Competition",
      "id": 136850298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "CVS strengthens Caremark's PBM edge with formulary shifts, new partnerships and cost-saving wins for clients.",
      "url": "https://finnhub.io/api/news?id=6ab643017ac2470a0b23e3fb3e0524ab2f46f27856d880ccdb1d8d6424ccae53"
    }
  },
  {
    "ts": null,
    "headline": "SEED Therapeutics Completes $30 Million Series A-3 Financing",
    "summary": "KING OF PRUSSIA, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers, today announced the successful completion of its $30 million Series A-3 financing, alongside U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for its lead program targeting RBM39. The company anticipates entering first-in-human",
    "url": "https://finnhub.io/api/news?id=f804cb51b10ef6a1d8bdceaa5b074d3a7ac9528a1979d5327a082dd6a1a9564d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758625200,
      "headline": "SEED Therapeutics Completes $30 Million Series A-3 Financing",
      "id": 136850299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "KING OF PRUSSIA, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers, today announced the successful completion of its $30 million Series A-3 financing, alongside U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for its lead program targeting RBM39. The company anticipates entering first-in-human",
      "url": "https://finnhub.io/api/news?id=f804cb51b10ef6a1d8bdceaa5b074d3a7ac9528a1979d5327a082dd6a1a9564d"
    }
  },
  {
    "ts": null,
    "headline": "This Hated Stock Suddenly Looks Like an Obesity Bargain",
    "summary": "Pfizer’s latest deal could make it the budget entry point to the weight-loss bonanza.",
    "url": "https://finnhub.io/api/news?id=7ecdd5182b6e8f7715ec43ddb4b17e33705785584c0bfe49734efb2f42abf830",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758619800,
      "headline": "This Hated Stock Suddenly Looks Like an Obesity Bargain",
      "id": 136850300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pfizer’s latest deal could make it the budget entry point to the weight-loss bonanza.",
      "url": "https://finnhub.io/api/news?id=7ecdd5182b6e8f7715ec43ddb4b17e33705785584c0bfe49734efb2f42abf830"
    }
  },
  {
    "ts": null,
    "headline": "India's Fortis to expand obesity clinics amid weight-loss therapy boom, CEO says",
    "summary": "NEW DELHI (Reuters) -India's Fortis Healthcare plans to open more dedicated obesity clinics across its hospitals to meet surging demand for weight-loss drugs and therapies in the world's most populous nation, its CEO told Reuters.  The India launch of popular weight-loss drugs such as Eli Lilly's Mounjaro and Novo Nordisk's Wegovy this year has heightened patient awareness in the nation projected to have the world's second-largest population of obese people by 2050.  \"We are witnessing a sharp rise in patient interest and demand for structured guidance on weight management and newer obesity-related therapies,\" Fortis Managing Director and Chief Executive, Ashutosh Raghuvanshi, said in an interview earlier this month.",
    "url": "https://finnhub.io/api/news?id=869758c149de8461893396e2170bf5d78f5295c5f6fef8f0a71e61132c59750e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758612831,
      "headline": "India's Fortis to expand obesity clinics amid weight-loss therapy boom, CEO says",
      "id": 136850301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NEW DELHI (Reuters) -India's Fortis Healthcare plans to open more dedicated obesity clinics across its hospitals to meet surging demand for weight-loss drugs and therapies in the world's most populous nation, its CEO told Reuters.  The India launch of popular weight-loss drugs such as Eli Lilly's Mounjaro and Novo Nordisk's Wegovy this year has heightened patient awareness in the nation projected to have the world's second-largest population of obese people by 2050.  \"We are witnessing a sharp rise in patient interest and demand for structured guidance on weight management and newer obesity-related therapies,\" Fortis Managing Director and Chief Executive, Ashutosh Raghuvanshi, said in an interview earlier this month.",
      "url": "https://finnhub.io/api/news?id=869758c149de8461893396e2170bf5d78f5295c5f6fef8f0a71e61132c59750e"
    }
  },
  {
    "ts": null,
    "headline": "Lilly’s Alzheimer’s efforts depend on newer, better biomarkers and diagnostics",
    "summary": "The pharma giant’s R&D in Alzheimer’s didn’t end with last year’s Kisunla approval, and diagnostics could define where the company goes next.",
    "url": "https://finnhub.io/api/news?id=d4d1692995421e26388bf68f7684a2577a7e672a4126c7cc86a929825ab75d46",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758611461,
      "headline": "Lilly’s Alzheimer’s efforts depend on newer, better biomarkers and diagnostics",
      "id": 136850302,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharma giant’s R&D in Alzheimer’s didn’t end with last year’s Kisunla approval, and diagnostics could define where the company goes next.",
      "url": "https://finnhub.io/api/news?id=d4d1692995421e26388bf68f7684a2577a7e672a4126c7cc86a929825ab75d46"
    }
  },
  {
    "ts": null,
    "headline": "Roche's Giredestrant: A Ray Of Hope On A Cloudy Horizon?",
    "summary": "Swiss pharmaceutical and diagnostics giant Roche Holding has finally released some positive news about its oral breast cancer drug giredestrant, which...",
    "url": "https://finnhub.io/api/news?id=2efc93792c1b331494916e840656503106e5f3a92a2c0f1f6b4a81b2a45d6d96",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758610143,
      "headline": "Roche's Giredestrant: A Ray Of Hope On A Cloudy Horizon?",
      "id": 136848827,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177198939/image_2177198939.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Swiss pharmaceutical and diagnostics giant Roche Holding has finally released some positive news about its oral breast cancer drug giredestrant, which...",
      "url": "https://finnhub.io/api/news?id=2efc93792c1b331494916e840656503106e5f3a92a2c0f1f6b4a81b2a45d6d96"
    }
  },
  {
    "ts": null,
    "headline": "Celltrion unit pays $330 million for Eli Lilly production facility, filing shows",
    "summary": "Celltrion Inc. said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems LLC from Eli Lilly in the United States for $330 million. In a statement, Celltrion said it aimed to complete the factory acquisition process by year-end in cooperation with its partner.",
    "url": "https://finnhub.io/api/news?id=53c88a9bf0885486ef46f70b17ca2eab9c352661ece6f1b35ef32e7541cd174f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758591135,
      "headline": "Celltrion unit pays $330 million for Eli Lilly production facility, filing shows",
      "id": 136850303,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Celltrion Inc. said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems LLC from Eli Lilly in the United States for $330 million. In a statement, Celltrion said it aimed to complete the factory acquisition process by year-end in cooperation with its partner.",
      "url": "https://finnhub.io/api/news?id=53c88a9bf0885486ef46f70b17ca2eab9c352661ece6f1b35ef32e7541cd174f"
    }
  }
]